| 培美曲塞单药对比多西紫杉醇二线治疗晚期非小细胞肺癌的系统评价 |
| |
| 引用本文： | 白瑶,段京莉.培美曲塞单药对比多西紫杉醇二线治疗晚期非小细胞肺癌的系统评价[J].中国新药杂志,2011(19). |
| |
| 作者姓名： | 白瑶 段京莉 |
| |
| 作者单位： | 北京大学药学院药事管理与临床药学系;北京大学深圳医院药剂科;北京大学第三医院药剂科; |
| |
| 摘 要： | 目的:比较培美曲塞单药与多西紫杉醇单药二线治疗晚期非小细胞肺癌的临床疗效和安全性。方法:采用Cochrane系统评价方法进行资料提取、分析、评价,并使用RevMan 5.0软件进行Meta分析。结果:共纳入5个研究,916例晚期非小细胞肺癌(NSCLC)患者。Meta分析结果显示,与对照组多西紫杉醇相比,培美曲塞治疗晚期NSCLC的总反应率、一年生存率、疾病控制率等的差别无统计学意义,可以认为二者疗效相当。不良反应方面,培美曲塞和多西紫杉醇在轻度及重度中性粒细胞减少、重度血小板下降和轻度脱发方面的发生率方面的差异具有统计学意义。其中,在轻度及重度中性粒细胞减少和轻度脱发方面培美曲塞优于多西紫杉醇,而在重度血小板下降方面多西紫杉醇优于培美曲塞。在其他各个方面的不良反应发生率中,两组差异没有统计学意义。结论:培美曲塞单药二线治疗晚期NSCLC的疗效确切。与多西紫杉醇比较,二者疗效差异不明显,不良反应发生率存在一些差异。
|
| 关 键 词： | 培美曲塞 多西紫杉醇 晚期非小细胞肺癌 系统评价 |
Pemetrexed alone versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer: a systematic review |
| |
| BAI Yao,DUAN Jing-li.Pemetrexed alone versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer: a systematic review[J].Chinese Journal of New Drugs,2011(19). |
| |
| Authors: | BAI Yao DUAN Jing-li |
| |
| Affiliation: | BAI Yao1,3,DUAN Jing-li1,2(1 Department of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Sciences,Peking University,Beijing 100083,China,2 Department of Pharmacy,The Third Hospital of Peking University,3 Department of Pharmacy,Peking University Shenzhen Hospital,Shenzhen 518036,China) |
| |
| Abstract: | Objective:To compare and evaluate the effectiveness and safety of pemetrexed alone versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer(NSCLC).Methods:Search strategy,sample selection,assessment,data collection and analysis were undertaken by two authors according to the Cochrane handbook for systematic reviews,and the Meta-analyses were performed using RevMan 5.0 software.Results:Five RCTs involving 916 patients were included.The results of meta-analyses showed th... |
| |
| Keywords: | pemetrexed docetaxel non-small-cell lung cancer systematic review |
| 本文献已被 CNKI 等数据库收录！ |
|
